Vir’s flu-prevention drug fails mid-stage clinical trial, stock dips

Vir had hoped the monoclonal antibody’s clinical trial would provide an added layer of protection for the elderly and other who remained at-risk despite flu vaccines.
Click here to view original post

Advertisement — Advertise with Biotech Networks